- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02002715
Therapeutic Effect of Different Treatment Course With Inhaled Corticosteroids in Eosinophilic Bronchitis Patients
Randomised, Open-label, Parallel-group Study of Therapeutic Effect of Different Treatment Course With Inhaled Corticosteroids in Eosinophilic Bronchitis Patients
This study aims to observe the therapeutic effect of different treatment course with inhaled corticosteroids in eosinophilic bronchitis patients.
The investigators hypothesize:
- Cough score will be improved after treatment with longer treatment course with inhaled corticosteroids in EB patients.
- The sputum eosinophil percentage will be decreased and recovered to normal level (Eos%<2.5%) with longer treatment course with inhaled corticosteroids in EB patients.
- The rate of recurrence after treatment will be decrease with longer treatment course with inhaled corticosteroids in EB patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study groups:
Patients diagnosed with EB will be randomised into three groups as follows:
Group 1(4-week treatment group):The patients with eosinophilic bronchitis received Pulmicourt Turbuhaler (Budesonide 100µg) 2puff Q12h for 4 weeks.
Group 2(8-week treatment group):The patients with eosinophilic bronchitis received Pulmicourt Turbuhaler (Budesonide 100µg) 2puff Q12h for 8 weeks.
Group 3(16-week treatment group):The patients with eosinophilic bronchitis received Pulmicourt Turbuhaler (Budesonide 100µg) 2puff Q12h for 16 weeks.
The study will be divided into following phases:
First Visit (Visit 1, day -3):
A full medical history and physical examination to be undertaken to determine whether patients meet the inclusion/exclusion criteria.
After the informed consent has been signed, the following samples are obtained from all patients: blood samples for routine clinical laboratory tests (haematology, biochemistry and chest x-ray). A urine pregnancy test will be performed in women of childbearing potential.
Bronchial provocation test by methacholine inhalation are performed to determined whether it presences of bronchial non-specific hyper-responsiveness. Hypertonic saline induced sputum samples for cell differential is taken to determine whether it esixt eosinophilic airway inflammation.
Second Visit (Visit 2, Week 0):
A physical examination was to be performed. All laboratory tests results are obtained to determine whether patients meet the inclusion/exclusion criteria. Enrolled patients are randomly divided into three groups with inhaled budesonide 200 µg twice daily via a turbohaler for 4 weeks, 8 weeks and 16 weeks respectively and given the Diary Card.
During Treatment (Week 0 to Week 4/8/16,every 4 weeks):
Patients were to take study medication for 4 weeks in 4-week group,8 weeks in 8-week group,16 weeks in 16-week group. All patient are followed-up every 4 weeks and completed Diary Card for 7 days in the last week of treatment.
Third Visit (Visit 3, Week 4/8/16):
A physical examination were to be performed. The Diary Card were collected and reviewed. Adverse events, secondary complications, concurrent medication will be recorded.Hypertonic saline induced sputum samples for cell differential is taken from enrolled patients.Blood samples for routine clinical laboratory tests (haematology and biochemistry) were obtained
- Follow-up visits were conducted after 1 year and whenever recurrence of cough :Cough symptom score,visual analogue scale (VAS), spiromery and induced sputum for cell differential is taken from enrolled patients.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 520120
- Guangzhou Institute of Respiratory Disease
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients who have a history of cough as sole or main symptom lasting more than 3 weeks.
- Patients whose chest x-ray outcome was normal or without any active focus.
- Patients who were diagnosed with the result of sputum eosinophil percentage (Eos%) over 2.5%, and the negative result in bronchial provocation test by methacholine inhalation challenge.
- Patients who was aged from 18 years old (≥ 18 years old ) to 75 years old (≤ 75 years old).
Exclusion Criteria:
- Patients who is a smoker or ex-smoker and has smoked within the previous year or has a cumulative smoking history >10 pack-years or equivalence.
- Patients with concomitance of GERC (gastroesophageal reflux-related chronic cough), chronic bronchitis , bronchiectasis, bronchial tuberculosis, ACEI induced cough, bronchogenic carcinoma, psychologic cough, pulmonary fibrosis, bronchus foreign body, microlithiasis, tracheobroncheopathia osteochondroplastica, mediastinal tumor, left ventricular dysfunction.
- Female subjects who are pregnant, breast-feeding or risk of becoming pregnant during the study.
- Subjects who are known or suspected to be hypersensitive to any component of the study medication or relief medications.
- Subjects who have received any therapy in the previous 4 weeks, e.g.corticosteroids ,antihistamines, leukotriene receptor antagonist in previous 4 weeks
- Subjects who are diagnosed with past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease. e.g.nasal-sinus infection, lower respiratory tract infection, chronic bronchitis, emphysema, bronchiectasis, cystic fibrosis or bronchopulmonary dysplasia.
Subjects who demonstrate significant abnormality on biochemistry, hematology, ECG.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Inhaled budesonide for 4 weeks
inhaled Budesonide 100µg , 2puff Q12h for 4 weeks
|
inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
Other Names:
|
Active Comparator: Inhaled budesonide for 8 weeks
inhaled Budesonide 100µg , 2puff Q12h for 8 weeks
|
inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
Other Names:
|
Active Comparator: Inhaled budesonide for 16 weeks
inhaled Budesonide 100µg , 2puff Q12h for 16 weeks
|
inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary outcome was the relapse rate of eosinophilic bronchitis in one year.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change in percentage of eosinophil in induced sputum from baseline to post-treatment
Time Frame: week 0,week 4,week 8,week 16
|
week 0,week 4,week 8,week 16
|
change in Cough visual analogue scale (VAS) and Cough Symptom Score (CSS) from baseline to post-treatment
Time Frame: week 0,week 4,week 8,week 16
|
week 0,week 4,week 8,week 16
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Disease Attributes
- Bronchial Diseases
- Lung Diseases, Obstructive
- Acute Disease
- Bronchitis
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Budesonide
Other Study ID Numbers
- cough001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eosinophilic Bronchitis
-
McMaster UniversitySt. Joseph's Healthcare Hamilton; Teva Pharmaceuticals USACompletedSevere Persistent Asthma | Eosinophilic BronchitisCanada
-
Guangzhou Medical UniversityUnknownNonasthmatic Eosinophilic BronchitisChina
-
McMaster UniversityGlaxoSmithKline; University of ManchesterRecruitingAsthma | Eosinophilic Bronchitis | Chronic CoughCanada
-
McMaster UniversityNovartisCompletedEosinophilic Bronchitis | Steroid and/or Prednisone Dependent AsthmaCanada
-
The First Affiliated Hospital of Guangzhou Medical...UnknownEosinophilic Bronchitis | Cough Variant AsthmaChina
-
Ann & Robert H Lurie Children's Hospital of ChicagoRecruitingEosinophilic Gastroenteritis | Eosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic Gastrointestinal DiseaseUnited States
-
IRCCS Policlinico S. MatteoItalian Society of Pediatric Allergy & Immunology - Pediatric CentersRecruitingEosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic Gastritis or Gastroenteritis | Eosinophilic Gastrointestinal DisordersItaly
-
Children's Hospital Medical Center, CincinnatiNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsRecruitingEosinophilic Gastritis | Eosinophilic Gastroenteritis | Eosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic Gastrointestinal Disorders (EGIDs)United States
-
Allakos Inc.CompletedEosinophilic Gastritis | Eosinophilic DuodenitisUnited States
-
Children's Hospital Medical Center, CincinnatiNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsCompletedEosinophilic Gastritis | Eosinophilic Gastroenteritis | Eosinophilic Esophagitis | Eosinophilic ColitisUnited States
Clinical Trials on Inhaled budesonide
-
Pearl Therapeutics, Inc.Completed
-
Sun Yat-sen UniversityJIANGSU JIBEIER PHARMACEUTICAL CO.,LTDNot yet recruitingNasopharyngeal Carcinoma | Chemotherapy | Myelosuppression | LeucogenChina
-
Government Medical College, BhavnagarCompletedModerate to Severe Persistent Bronchial AsthmaIndia
-
University of North Carolina, Chapel HillAstraZenecaCompletedEosinophilic EsophagitisUnited States
-
Sara VareaCompletedCoronavirus InfectionSpain, Argentina
-
Instituto Nacional de Cancerologia de MexicoInstituto Nacional de Enfermedades RespiratoriasRecruitingRadiation PneumonitisMexico
-
University of British ColumbiaNational Cancer Institute (NCI)Completed
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...RecruitingPneumonia | COVID-19 Pneumonia | Hypoxemia | Acute Respiratory FailureUnited States
-
Vanderbilt UniversityEmory University; Children's National Research InstituteCompletedAsthma | Sickle Cell Disease | Acute Chest SyndromeUnited States
-
Synspira, Inc.TerminatedLung Diseases | Cystic Fibrosis | Pulmonary Disease | Antibiotic Resistant Infection | Respiratory Tract Disease | Cystic Fibrosis Pulmonary Exacerbation | Lung Inflammation | Burkholderia Infections | Lung Infection | Multi-antibiotic Resistance | Pulmonary Inflammation | Lung Infection Pseudomonal | Cystic Fibrosis... and other conditionsUnited Kingdom